The slider hasn't been found

CME Info

TOS Review Course for the ABOM Exam
The Obesity Society Review Course (TOS) for the American Board of Obesity Medicine Exam provides a stimulating educational experience that helps prepare attendees for the ABOM Exam and thereby become an ABOM Diplomat. The TOS Review Course follows the ABOM rubric, giving attendees concise and yet sufficiently detailed material to enhance knowledge of the exam materials and exam questions. Included in registration for this course is a downloadable course workbook.

TOS Review Course for the American Board of Obesity Medicine Exam OnDemand 2019 is a digital library of 18 hours of educational content originally presented live at the TOS Review Course for the ABOM Exam, November 3-4, 2019 in Las Vegas, NV.

TOS Review Course for the ABOM Exam OnDemand features:

  • Online access to presenters’ slides with synchronized audio
  • Searchable slide content
  • Earn up to 18 AMA PRA Category 1 Credits™
  • PC and MAC Compatible
  • Mobile version for most smartphone and tablet devices

TOS Review Course for the ABOM Exam is designed to prepare learners for the ABOM examination. It is designed to increase attendees’ knowledge and competence regarding the treatment of patients with obesity by addressing the following issues: evaluation, treatment plans, post-bariatric surgery consideration, basic science fundamentals, and environmental factors.

Target Audience
The intended audience for this activity consists of health care providers of people who are obese and includes the following groups: clinicians/primary care physicians (general medicine, internal medicine, family practice), endocrinologists, surgeons, pediatricians, nurses/nurse practitioners, rehabilitation/exercise therapists, mental health providers, physical/occupational therapists, and dieticians/nutritionists.

Educational Need

  1. Physicians need to know what evidence-based tools are available and how to use them to evaluate patients’ treatment needs and develop a course of treatment using the full spectrum of available options.
  2. Physicians need evidence-based knowledge about and implementation strategies for diet and exercise, behavioral/cognitive therapies, pharmacotherapy and bariatric surgery for treating patients
  3. Physicians need knowledge about the evidence-based science of hormonal, neurological and gut and adipocyte interactions and the translation of that science into implementation strategies for clinical practice.

Program Objectives
The primary objectives of the course are to enable delegates to:

  1. Use evidence-based diagnostic/assessment tools to determine which treatment is most appropriate for specific patient types.
  2. Develop appropriate behavioral, pharmacological and bariatric approaches for the treatment of patients with obesity.
  3. Apply the options that are currently available to develop strategies to treat patients with obesity including dietary strategies, physical activity interventions, medications, and surgical options.
  4. Implement evidence-based approaches for the treatment of obesity and to be able to explain it in terms easily understood by the patient.
  5. Incorporate evidence-based factors that predispose patients to weight gain—including genetic factors, relevant neuropeptides, alterations in energy expenditure and environmental factors—into appropriate patient-treatment strategies.
  6. To acquire strategies that foster the translation of predispositions into appropriate clinical treatment for patients with obesity.

Important Dates

Date of Release: November 27, 2019
Date of Termination: November 27, 2021
Please note that credit will only be available through the term of approval noted above.

Accreditation Statement
The Obesity Society is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
The Obesity Society designates this enduring material for a maximum of 18 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use
This educational activity may contain the discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration (FDA). The Obesity Society does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified healthcare professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

Disclosure of Conflicts of Interest
The Obesity Society requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have (within the previous 12 months) as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by The Obesity Society for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All identified conflicts of interest have been resolved

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Faculty Disclosures:

  • Adam Tsai, MD – Nothing to Disclose
  • Maria Collazo-Clavell, MD – Nothing to Disclose
  • Joseph Skelton, MD, MS – Nothing to Disclose
  • William Donahoo, MD, FTOS – Nothing to Disclose
  • John Jakicic, PhD, FTOS – Consulting Fee: WW International (Weight Management)
  • Patrick O’Neil, PhD, FTOS – Contracted Research: NovoNordisk (Pharmaceuticals); WW International (Weight Management), Consulting Fee: Eli Lilly (Pharmaceuticals); Pfizer (Pharmaceuticals)
  • Harold Bays, MD, FTOS, FACC, FACE, FNLA – Contracted Research: Amgen (Pharmaceuticals); Eisai (Pharmaceuticals); Janssen (Pharmaceuticals); Novartis (Pharmaceuticals); NovoNordisk (Pharmaceuticals); Alon-Medtech (Pharmaceuticals), Consulting Fee: Regeneron (Pharmaceuticals)
  • Bruce Wolfe, MD, FACS, FASMBS – Nothing to Disclose
  • Michael Jensen, MD, FTOS – Nothing to Disclose

The planners and managers reported the following financial relationship or relationships they or their spouse/life partner have with commercial interests (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients) related to the content of this CME activity:

Planner Disclosures:

  • Maria Collazo-Clavell, MD – Nothing to Disclose
  • Jonathan Q. Purnell, MD, FTOS – Consulting Fee: Novo Nordisk (Pharmaceuticals)
  • Ninoska Peterson, PhD – Nothing to Disclose
  • Theodore J. Angelopoulos, PhD – Nothing to Disclose
  • Michael McClurkan, MD – Nothing to Disclose
  • Lynda Mandell, MD, PhD – Nothing to Disclose
  • Nihar Shah, MD – Nothing to Disclose
  • Leon I. Igel, MD, FACP, FTOS – Consulting Fee: Novo Nordisk (Pharmaceuticals), Ownership Interest (excluding mutual funds): Intellihealth (Weight Management)
  • Adam G. Tsai, MD, MSCE, FACP – Nothing to Disclose

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

  • John B. Cleek, MD – Nothing to Disclose
  • Dong Wook Kim, MD, PNS – Nothing to Disclose
  • Van Hubbard, MD – Nothing to Disclose
  • Jaime Almandoz, MD – Nothing to Disclose
  • Alpana Shukla, MD – Nothing to Disclose
  • Jason Block, MD – Nothing to Disclose
  • Adam G. Tsai, MD, MSCE, FACP – Nothing to Disclose

Acknowledgment of Commercial Support
This activity has not received any commercial support.

Method of Participation and CME/CE Certificates
This activity is certified for up to 18 AMA PRA Category 1 Credits™ or a Certificate of Participation for other healthcare professionals based on the time you spend watching presentations and taking the post-test questions. You may re-enter the product as many times as you wish, but you can claim CME credit only once.

To receive CME/CE credit for this product, you must:

  1. Purchase the product.
  2. Read the CME/CE Information available when you first enter the player or by clicking the CME Info link in the top right corner.
  3. Take the pre-test.
  4. View the session(s) of your choosing.
  5. Click the Test link in the top right corner after you have completed viewing all sessions for which you intend to claim credit.
  6. Complete the post-test.
  7. Enter the number of credits you wish to claim (up to a maximum of 18 credits).  Credits claimed should reflect the total number of hours that you spent reviewing the CME/CE information, watching sessions and taking the post-test. (*Please Note: If you already claimed credit for attending the TOS Review Course for the ABOM Exam meeting, you cannot claim credit for the same sessions on TOS Review Course for the ABOM Exam OnDemand).
  8. Generate and print your CME/CE certificate.

*Disclaimer* The content of any practice question is determined solely by The Obesity Society, and the American Board of Obesity Medicine (ABOM) and ABOM’s current and former Board members, officers, employees, and committee members do not create content for, create materials for, write items for, or in any way participate in the formation of such practice questions and do not in any way control, review, or monitor the quality of such practice questions.

Medium or Combination of Medium Used:
TOS Review Course for the ABOM Exam OnDemand is available online on most mobile devices, including smartphones and tablets.

Hardware/Software Requirements
For the most current list of system requirements, please visit

Provider Contact Information
The Obesity Society Customer Support:
[email protected]

The Obesity Society Contact Information
The Obesity Society
1110 Bonifant Street Suite, 500
Silver Spring, MD 20910
Phone: (301) 563-6526
[email protected]

Technical Issues Contact Information
Should you encounter technical issues using this site, please contact [email protected].

Fee & Refund Policy
There is a fee for this educational activity. Once purchased, there are no refunds.

Privacy Policy

This website is provided by Wolters Kluwer N.V. and/or its subsidiaries. By using this Website you consent to the use of your Personal Data as described in our Privacy Policy (“Policy”).

The Privacy Policy can be found at and may be updated at any time.

D Al-Hamad, V Raman “Metabolic syndrome in children and adolescents.” Transl Pediatr. 2017 Oct;6(4):397-407.

EA O’Connor, CV Evans, BU Burda, ES Walsh, M Eder, P Lozano “Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA. 2017 Jun 20;317(23):2427-2444.

AG Tsai et all, “Evidence of a Gap in Understanding, Obesity Among Physicians.” Obesity, Science and Practice Online 1/12/18, DOI: 10/1002/asp4.416

Kelly AS, Barlow SE, Rao G, Inge TH, Hayman LL, Steinberger J, Urbina EM, Ewing LJ, Daniels SR; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young, Council on Nutrition, Physical Activity and Metabolism, and Council on Clinical Cardiology “Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association”

Circulation. 2013 Oct 8;128(15):1689-712. doi: 10.1161/CIR.0b013e3182a5cfb3. Epub 2013 Sep 9.

JS Yeh et al. “Obesity and Management of Weight Loss.” N Engl J Med 2016; 375:1187-1189

Jensen MD, et all. “Guidelines (2013) for managing overweight and obesity in adults.” Obesity 2014;22(S2):S1-S410.

Apovian CM1, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD; Endocrine Society. “Pharmacological management of obesity: an endocrine Society clinical practice guideline.”  J Clin Endocrinol Metab. 2015 Feb;100(2):342-62.

SB Heymsfield and TA Wadden “Mechanisms, Pathophysiology, and Management of Obesity.” N Engl J Med 2017;376:254-266

MW Schwartz, RJ Seeley, LM Zeltser, A Drewnowski, E Ravussin, LM Redman, RL Leibel “Obesity Pathogenesis.” Endocr Rev. 2017 Aug 1;38(4):267-296.